Final answer:
The EMA has guidelines for the conduct of comprehensive and select license EAs, but the cited documents do not state the number of condition sets. Comprehensive EAs usually require a thorough evaluation, whereas select EAs are more customized.
Step-by-step explanation:
The European Medicines Agency (EMA) has established specific guidelines for the conditions under which comprehensive license Environmental Assessments (EAs) and select license EAs are to be conducted.
However, the two documents cited, EMA (2012) Guideline on Investigation of Drug Interactions and EMA (2008) Note for Guidance on Non-clinical Safety Studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals do not directly specify the number of sets of conditions for these EAs.
Comprehensive license EAs generally require broader and more detailed evaluation compared to select license EAs, which may be tailored to specific circumstances. The precise conditions can vary depending on the nature of the pharmaceutical or clinical trial in question.
For targeted guidance on environmental assessments, one would need to refer to the appropriate EMA guidelines or regulatory documents that specifically address environmental assessment requirements for licensing.